Tuo Xin Pharmaceutical Group Co., Ltd. (hereinafter referred to as the Group) is a high-tech enterprise integrating research and development, production, and sales of chemical synthesis, and nucleoside (acid) pharmaceutical and pharmaceutical intermediates. The Group has strong capabilities in the research, development, and production of nucleoside (acid) pharmaceutical and pharmaceutical intermediates in the domestic market.
In the field of research and development of nucleoside (acid) pharmaceutical and pharmaceutical intermediates in China, the Group has advantages such as an early start, large scale, and a complete variety, forming a relatively complete product chain from basic to high-end products. The Group has established efficient catalytic synthesis reaction technology platform, nucleoside fermentation technology platform, and bioconversion semi-synthesis technology platform. It has formed multiple series of nucleoside (acid) products, including raw materials and pharmaceutical intermediates such as cytidine choline sodium, ribavirin, adenosine, cytosine, 5-fluorocytidine, and cytidine, covering areas such as antiviral, antitumor, and neurology.
In terms of production management, the Group's subsidiary companies have passed the ISO9001 quality management system certification, implementing full-process control from product design and development, raw material procurement, process control to product sales. In the production of active pharmaceutical ingredients, the Group's subsidiaries implement GMP management, and multiple products have obtained GMP certification.
The Group actively conducts various certifications and registrations for its products domestically and internationally. Several subsidiary products have passed India, Uzbekistan DMF certification, and multiple pharmaceutical intermediate products have obtained official certifications from countries and regions such as Japan and the European Union, including EU REACH registration certificates, HALAL certification, and KOSHER certification.
The Group always focuses on "research and development innovation" as its core, attaching great importance to investment in product research and development and the enhancement of its own comprehensive research and development capabilities. Its subsidiary companies have established the "Postdoctoral Research and Development Base of Henan Province" and the "National Postdoctoral Research Workstation," and have been recognized as the "National High-tech Industry Demonstration Project," the first batch of leading enterprises in Henan Province's high-tech special industry base, "Henan Enterprise Technology Center," and "Henan Province Nucleoside Engineering Technology Research Center." They have received significant science and technology awards, including the first prize for scientific and technological progress in Henan Province and the second prize for national scientific and technological progress. Multiple products have been selected as "National Key New Products" and "National Torch Program Projects."
